A phase II clinical study of bevacizumab plus cisplatin and pemetrexed in patients with wild‐type EGFR advanced non‐squamous NSCLC showed a mPFS of 12.0 months, a mOS of 31.0 months, and an ORR of 70%. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.